» Articles » PMID: 33596735

Successful Integration of HIV Pre-exposure Prophylaxis into a Community-based HIV Prevention Program for Female Sex Workers in Kolkata, India

Overview
Journal Int J STD AIDS
Date 2021 Feb 18
PMID 33596735
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

We assessed the impact of pre-exposure prophylaxis (PrEP) in the context of a community-based HIV program among female sex workers (FSWs) in Kolkata, India. This was an open-label, uncontrolled demonstration trial. HIV seronegative FSWs over 18 years were eligible. Participants were administered daily tenofovir/emtricitabine (TDF-FTC) with follow-up visits at months 1, 3, 6, 9, 12, and 15. Drug adherence was monitored by self-report, and a random subset of participants underwent plasma TDF testing. 843 women were screened and 678 enrolled and started on PrEP. Seventy-nine women (11%) did not complete all scheduled visits: four women died of reasons unrelated to PrEP and 75 withdrew, for a 15-month retention rate of 89%. Self-reported daily adherence was over 70%. Among those tested for TDF, the percentage of women whose level reached ≥40 ng/mL was 65% by their final visit. There were no HIV seroconversions, and no evidence of significant changes in sexual behavior. This study demonstrated the feasibility and effectiveness of PrEP for FSWs in Kolkata, with very high levels of adherence to PrEP and no HIV seroconversions. The integration of PrEP into an existing community-based HIV prevention program ensured community support and facilitated adherence.

Citing Articles

What will it take to expand the pre-exposure prophylaxis to prevent new HIV infections in India?.

Gaur A, Rakhmanina N Indian J Med Res. 2025; 160(6):527-529.

PMID: 39913518 PMC: 11801762. DOI: 10.25259/IJMR_2102_2024.


Assessment of acceptance and associated factors of HIV pre-exposure prophylaxis among commercial female sex workers in drop-in centers selected sub-cities of Addis Ababa, Ethiopia.

Berhe T, Asfaw E, Tedla G Front Public Health. 2024; 12:1462648.

PMID: 39678245 PMC: 11638227. DOI: 10.3389/fpubh.2024.1462648.


HIV preexposure prophylaxis and postexposure prophylaxis in women: a comprehensive guide for healthcare providers.

Vora N, Badowski M Ther Adv Infect Dis. 2024; 11:20499361241300920.

PMID: 39650692 PMC: 11624534. DOI: 10.1177/20499361241300920.


Social disparities on PrEP use and awareness among sexual and gender minorities using smartphones in India.

Agarwal H, Yeatts K, Chung S, Harrison-Quintana J, Torres T Ther Adv Infect Dis. 2024; 11:20499361241299992.

PMID: 39575203 PMC: 11580082. DOI: 10.1177/20499361241299992.


Advancing Programme Science approaches to understand gaps in HIV prevention programme coverage for key populations in 12 Nigerian states: findings from the 2020 Integrated Biological and Behavioural Surveillance Survey.

McClarty L, Green K, Leung S, Ejeckam C, Adesina A, Shaw S J Int AIDS Soc. 2024; 27 Suppl 2:e26269.

PMID: 38988042 PMC: 11236907. DOI: 10.1002/jia2.26269.


References
1.
Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

2.
Donnell D, Baeten J, Bumpus N, Brantley J, Bangsberg D, Haberer J . HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66(3):340-8. PMC: 4059553. DOI: 10.1097/QAI.0000000000000172. View

3.
Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

4.
Traeger M, Schroeder S, Wright E, Hellard M, Cornelisse V, Doyle J . Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018; 67(5):676-686. DOI: 10.1093/cid/ciy182. View

5.
Agot K, Taylor D, Corneli A, Wang M, Ambia J, Kashuba A . Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. AIDS Behav. 2014; 19(5):743-51. PMC: 4415940. DOI: 10.1007/s10461-014-0859-z. View